Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS guidance. See more on PFE stock here.

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

Analysts estimate that Pfizer will report an earnings per share (EPS) of $0.58. The market awaits Pfizer's announcement, with ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

As Wall Street embarks on the first full week of August, the earnings wave continues with another stacked week of reports ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $25.0 for Pfizer, spanning the last three months.

2. Pfizer's positives aren't fully reflected in its valuation You might think Wall Street would be overwhelmingly bearish about Pfizer in light of its challenges. However, that isn't the case.